Science News
from research organizations

Researchers identify protein to help predict who will respond to PD-1 immunotherapy for melanoma

Date:
September 16, 2015
Source:
Mayo Clinic
Summary:
Researchers have identified a protein marker whose frequency may predict patient response to PD-1 blockade immunotherapy for melanoma.
Share:
FULL STORY

Mayo Clinic researchers have identified a protein marker whose frequency may predict patient response to PD-1 blockade immunotherapy for melanoma. An abstract of their findings was presented at the American Association for Cancer Research International Cancer Immunotherapy Conference in New York City.

"The discovery of biomarkers of sensitivity are vital not only for informing clinical decisions, but also to help identify which patients with melanoma, and possibly other malignancies, who are most likely to benefit from PD-1 blockade," says Roxana Dronca, M.D., a hematologist at Mayo Clinic and lead author of the abstract. "This will allow us to expose fewer patients to inadequate treatments, and their associated toxicities and costs."

The marker, Bim, is a protein that helps coordinate programmed cell death. This is a natural process that occurs in many cells, including T cells, a subset of immune cells that can recognize and kill tumor cells. Interaction of a molecule called PD-1 on T cells with a molecule called PD-L1 activates Bim and can induce T cell death. Tumors can exploit this process by overexpressing PD-L1 and killing T cells that could recognize and eliminate them.

In an effort to overcome the problem of tumors evading the immune system, researchers have generated biological molecules that block PD-1 from interacting with PD-L1. These PD-1 blockers have shown promise results in some cancer patients, but not others -- prompting a search for markers that could predict how patients will respond to the molecules before treatment.

"If I know that a patient has a very high likelihood of responding to anti-PD-1 therapy, I'm going to be more inclined to recommend that treatment and feel better about the choice," Dr. Dronca says.

Researchers found that metastatic melanoma patients who responded to PD-1 blockade with pembrolizumab had more tumor-targeting T cells expressing Bim and PD-1 in their blood prior to therapy than did patients who did not respond. They also observed that this trend reversed after weeks of treatment suggesting that proportions of these cells can be measured to help clinicians decide which patients should and should not be treated with PD-1 blockade.

They also discovered that responders had higher levels of soluble PD-L1 in their blood prior to treatment. This suggests that PD-1 blockade is most effective when the PD-1:PD-L1 interaction plays a major role in disease -- a finding that improves scientific understanding of the therapeutic mechanism of PD-1 blockade.


Story Source:

Materials provided by Mayo Clinic. Note: Content may be edited for style and length.


Cite This Page:

Mayo Clinic. "Researchers identify protein to help predict who will respond to PD-1 immunotherapy for melanoma." ScienceDaily. ScienceDaily, 16 September 2015. <www.sciencedaily.com/releases/2015/09/150916112436.htm>.
Mayo Clinic. (2015, September 16). Researchers identify protein to help predict who will respond to PD-1 immunotherapy for melanoma. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/09/150916112436.htm
Mayo Clinic. "Researchers identify protein to help predict who will respond to PD-1 immunotherapy for melanoma." ScienceDaily. www.sciencedaily.com/releases/2015/09/150916112436.htm (accessed May 23, 2017).

RELATED STORIES